Yang, Peng-jie
Zhao, Xiang-yu
Kou, Yao-hui
Liu, Jia
Ren, Xiang-yi
Zhang, Yuan-yuan
Wang, Zhi-dong
Ge, Zhen
Yuan, Wei-xin
Qiu, Chen
Tan, Bing
Liu, Qin
Shi, Yan-na
Jiang, Yuan-qing
Qiu, Cong
Guo, Li-he
Li, Jin-ying
Huang, Xiao-jun
Yu, Lu-yang
Article History
Received: 18 August 2023
Accepted: 1 April 2024
First Online: 27 May 2024
Competing interests
: LYY, PJY, WXY, JYL, LHG, JL authored a China patent (No. ZL 2019 1 0310688.6) held by Zhejiang University and Shanghai iCELL Biotechnology Co. Ltd for the “Use of hAESCs for the treatment of GVHD”. WXY and QL are employees of Shanghai iCELL Biotechnology Co. Ltd. The remaining authors declare no competing financial interests.
: The hAESCs were derived from placenta amniotic membrane of unrelated, unmatched healthy donors with informed patient consent approved by the Institutional Patients and Ethics Committee of the Second Affiliated Hospital of Zhejiang University School of Medicine (Ethics Code: 2020-799). All animal studies were approved by the Institutional Animal Care and Use Committee of Zhejiang University (ZJU20210127) and adhered to the Guide for the Care and Use of Laboratory Animals. The clinical trial was approved by the institutional review board of Peking University People’s Hospital (2018PHD006-01) and conducted under an investigational new stem cells application from the National Health Commission of China. All patients and donors provided written informed consent according to the Declaration of Helsinki. The trial was registered at as #NCT03764228.